ABVC BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ABVC BioPharma generated cash of -$4,235,845, which is more than the previous year. Cash used in financing activities reached the amount of $3,918,960 last year. Net change in cash is therefore -$674,948.
Cash Flow
| 2014 | 1.16K | 0 | -1.78K |
|---|---|---|---|
| 2015 | 3.36K | 0 | 995.54K |
| 2016 | -3.47M | 0 | 2.65M |
| 2017 | -1.68M | -7.49M | 9.32M |
| 2018 | -630.19K | -156.37K | 593K |
| 2019 | -3.13M | -35.29K | 3.08M |
| 2020 | -4.56M | -225.43K | 9.56M |
| 2021 | -7.59M | -805.96K | 9.99M |
| 2022 | -7.39M | -1.72M | 4.01M |
| 2023 | -4.23M | -360.18K | 3.91M |
ABVC Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.39M | 6.56M | 5.00M | 160.44K | 242.78K | 93.33K | 100.46K | 994.83K | -995.54K | 618 |
Operating activities | ||||||||||
Net income | -10.51M | -16.31M | -12.03M | -10.59M | -3.93M | -4.10M | -6.66M | -4.50M | -32.28K | -70 |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 28.53K | 23.79K | 11.99K | 37.14K | 55.08K | 43.61K | 43.99K | 0 | 0 | 0 |
Stock-based compensation expense | 1.63M | 7.03M | 5.30M | 4.14M | 22.31K | 0 | 155.4K | 1.29M | 30K | 0 |
| Deferred income tax benefit | 1.63M | 7.03M | 5.30M | 4.14M | 22.31K | 0 | 155.4K | 1.29M | 30K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 228.55K | -614.16K | -120.98K | 3.69K | -120.73K | 11.22K | -724 | 6.47M | 22.51K | 1.23K |
Inventories | 0 | 25.97K | -25.83K | -88.16K | 1.30K | 14.79K | 3.46K | 0 | 521 | 0 |
Accounts payable | 0 | 0 | -23.04K | -951 | 50.24K | -98.35K | -18.37K | 18.37K | 0 | 0 |
Cash generated by operating activities | -4.23M | -7.39M | -7.59M | -4.56M | -3.13M | -630.19K | -1.68M | -3.47M | 3.36K | 1.16K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | -1.60M | -107.54K | 0 | -17.80K | -156.37K | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -21.20K | -119.69K | -17.50K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | -338.98K | -1.60M | -680.91K | 0 | -17.80K | 0 | -7.80M | 0 | 0 | 0 |
Cash generated by investing activities | -360.18K | -1.72M | -805.96K | -225.43K | -35.29K | -156.37K | -7.49M | 0 | 0 | 0 |
Financing activities | ||||||||||
Common Stock Issued | 1.05M | 3.66M | 11.11M | 7.61M | 531.14K | 0 | 7.68M | 2.35M | 948.95K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 462.62K | 350K | -514.23K | -844.59K | 2.00M | -257K | 3.57M | 0 | 0 | 0 |
Cash used in financing activities | 3.91M | 4.01M | 9.99M | 9.56M | 3.08M | 593K | 9.32M | 2.65M | 995.54K | -1.78K |
Net Change In Cash | -674.94K | -5.17M | 1.56M | 4.84M | -82.33K | -37.19K | 156.46K | -821.29K | 998.90K | -618 |
Cash at end of period | 716.78K | 1.39M | 6.56M | 5.00M | 160.44K | 56.13K | 256.92K | 173.53K | 3.36K | 0 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |